ConductScience.org, home

Paper · 38201484

Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.

Pantaleo A and 10 others. Cancers (Basel), 2023. Cited by 11 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review. Papers, record 38201484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38201484

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.96
iCite
Revised in PubMed
2024-01-14
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pantaleo AAntoninohttps://orcid.org/0000-0001-9260-8109
2Forte GGiovanna
3Fasano CCandidahttps://orcid.org/0000-0001-5878-3480
4Lepore Signorile MMartina
5Sanese PPaola
6De Marco KKatia
7Di Nicola EElisabetta
8Latrofa MMarialaura
9Grossi VValentina
10Disciglio VVittoria

1 to 10 of 11Source PubMed

See all 11 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
IG-23794 2020-2024 to Cristiano SimoneItalian Association for Cancer ResearchPubMed
AIRC Felloship for Italy ID 26678-2021 to Martina Lepore SignorileItalian Association for Cancer ResearchPubMed
Ricerca Corrente 2021-2023 to Cristiano SimoneItalian Ministry of HealthPubMed
Ricerca Corrente 2022-2024 to Vittoria DisciglioItalian Ministry of HealthPubMed
Ricerca Corrente 2022-2024 to Candida FasanoItalian Ministry of HealthPubMed
Ricerca Corrente 2023-2025 to Valentina GrossiItalian Ministry of HealthPubMed
Starting Grant SG-2019-12371540 to Paola SaneseItalian Ministry of HealthPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References233

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,059,070Pancreatic cancer: Advances and challenges.Cell2023https://conductscience.org/library/papers/37059070PubMed
214,735,200Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.Br J Cancer2004https://conductscience.org/library/papers/14735200PubMed
335,805,029A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes.Cancers (Basel)2022https://conductscience.org/library/papers/35805029PubMed
437,313,463Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing.Front Oncol2023https://conductscience.org/library/papers/37313463PubMed
525,356,972BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.Genet Med2015https://conductscience.org/library/papers/25356972PubMed
634,547,082Pancreatic Cancer: A Review.JAMA2021https://conductscience.org/library/papers/34547082PubMed
730,721,664Early Detection of Pancreatic Cancer: Opportunities and Challenges.Gastroenterology2019https://conductscience.org/library/papers/30721664PubMed
835,625,944OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma.Biomedicines2022https://conductscience.org/library/papers/35625944PubMed
928,979,722Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a CDKN2A germline mutation carrier.World J Gastrointest Oncol2017https://conductscience.org/library/papers/28979722PubMed
1037,894,428Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort.Cancers (Basel)2023https://conductscience.org/library/papers/37894428PubMed

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42,877,528Strategy for early diagnosis of pancreatic cancer.Front Gastroenterol (Lausanne)2026https://conductscience.org/library/papers/42877528PubMed
42,177,254The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC.Sci Rep2026https://conductscience.org/library/papers/42177254PubMed
41,374,970KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?Cancers (Basel)2025https://conductscience.org/library/papers/41374970PubMed
41,315,260Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.Nat Commun2025https://conductscience.org/library/papers/41315260PubMed
40,804,928Differentiating Main-Duct IPMN from Chronic Pancreatitis Using Next-Generation Sequencing of Main Pancreatic Duct Fluid: A Pilot Study.Diagnostics (Basel)2025https://conductscience.org/library/papers/40804928PubMed
40,418,431Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant.Fam Cancer2025https://conductscience.org/library/papers/40418431PubMed
40,282,495Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials.Cancers (Basel)2025https://conductscience.org/library/papers/40282495PubMed
39,949,937TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.Am J Cancer Res2025https://conductscience.org/library/papers/39949937PubMed
39,860,372Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.J Clin Med2025https://conductscience.org/library/papers/39860372PubMed
39,684,385Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy.Int J Mol Sci2024https://conductscience.org/library/papers/39684385PubMed

1 to 10 of 12

See all 12 cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38201484

GET https://conductscience.org/api/papers/v1/38201484/references?page=2